Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: Normal tissue tolerances and toxicity

Cancer Control

Volumn 17, Issue 2, 2010, Pages 111-119

  Sawrie, Stephen M ^a,b   Fiveash, John B ^a,b   Caudell, Jimmy J ^a,b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CORTICOSTEROID; DIURETIC AGENT;

ANOREXIA; ARTICLE; ASCITES; CANCER CONTROL; CANCER MORTALITY; CLINICAL TRIAL; COLON PERFORATION; DEBRIDEMENT; DERMATITIS; DIARRHEA; DOSIMETRY; DUODENUM ULCER; ERYTHEMA; ESOPHAGUS VARICES; HUMAN; HYPERBARIC OXYGEN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TOXICITY; NAUSEA; RADIATION DOSE FRACTIONATION; RADIATION INDUCED LIVER DISEASE; RADIATION SICKNESS; SKIN PAIN; SKIN TOXICITY; STEREOTACTIC BODY RADIATION THERAPY;

EID: 77952347870     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481001700206     Document Type: Article

References (30)

1. Reed GB Jr, Cox AJ Jr. The human liver after radiation injury: a form of veno-occlusive disease. Am J Pathol. 1966;48(4):597-611.
2. Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31(5): 1237-1248.
3. Russell AH, Clyde C, Wasserman TH, et al. Accelerated hyperfrac-tionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys. 1993;27(1):117-123.
4. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109-122.
5. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18(11):2210-2218.
6. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53(4):810-821.
7. Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: clinical experience of the first thirty-one patients. Acta Oncol. 1995;34(6):861-870.
8. Kavanagh BD, Schefter TE, Cardenes HR, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006;45(7):848-855.
9. Potters L, Steinberg M, Rose C, et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2004;60(4):1026-1032.
10. RTOG/EORTC Late Radiation Morbidity Scoring Schema. Radiation Therapy Oncology Group Web site. http://www.rtog.org/members/toxicity/late.html). Accessed January 28, 2010.
11. Brenner DJ. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol. 2008;18(4):234-239.
12. Hall EJ. Radiobiology for the Radiologist. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
13. Gay HA, Niemierko A. A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Phys Med. 2007;23(3-4): 115-125.
14. Park C, Papiez L, Zhang S, Story M, et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(3):847-852.
15. Jirtle RL, Michalopoulos G, McLain JR, et al. Transplantation system for determining the clonogenic survival of parenchymal hepatocytes exposed to ionizing radiation. Cancer Res. 1981;41(9 Pt 1):3512-3518.
16. Jirtle RL, McLain JR, Strom SC, et al. Repair of radiation damage in noncycling parenchymal hepatocytes. Br J Radiol. 1982;55:847-851.
17. Clifton KH, Draper NR. Survival-curves of solid transplantable tumour cells irradiated in vivo: a method of determination and statistical evaluation; comparison of cell-survival and 32-P-uptake into DNA. Int J Radiat Biol Relat Stud Phys Chem Med. 1963;7:515-535.
18. Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol. 2006;45(7):831-837.
19. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19(1):164-170.
20. Schefter TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371-1378.
21. Wulf J, Hädinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001;177(12):645-655.
22. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7): 823-830.
23. Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006; 45(7):838-847.
24. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26(4):657-664.
25. Lax I, Blomgren H, Näslund I, et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994; 733(6):677-683.
26. Liang SX, Zhu XD, Xu ZY, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006;65(2):426-434.
27. Cheng JC, Wu JK, Lee PC, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys. 2004;60(5):1502-1509.
28. Dose Escalation Study for Primary Hepatocellular Carcinoma (SBF-HCC) (www.clinicaltrials.govidentifierNCT00243841). Accessed January 28, 2010.
29. Battula N, Srinivasan P, Madanur M, et al. Ruptured hepatocellular carcinoma following chemoembolization: a western experience. Hepatobiliary Pancreat Dis Int. 2007;6(1):49-51.
30. López-Benítez R, Radeleff BA, Barragán-Campos HM, et al. Acute pancreatitis after embolization of liver tumors: frequency and associated risk factors. Pancreatology. 2007;7(1):53-62.